ESMO 2026 SYMPOSIUM
SCLC
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
Learn more about the event
Therapy Areas
Drug Classes
Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
All
FEATURED
ILCS
Webinars
Articles
Industry Sponsored
Featured Sessions
The Reading Room
Articles & Research
Oct
07
2026
RESEARCH
BiomarkersSCLC
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
P. Hofman
Oct
05
2026
RESEARCH
SCLCImmunotherapies
Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry
M. Hochmair
Oct
04
2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies
Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation
N. FrostM. ReckA. Cortellini
Oct
04
2026
RESEARCH
SCLCImmunotherapies
Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC
S. LiuM. ReckC. Rudin
Sep
30
2026
RESEARCH
Advanced NSCLCSCLCADCs
Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis
C. Rolfo
Sep
18
2026
CONGRESS
SCLCADCs
Ris-Rez improved OS against topotecan in relapsed SCLC in China
Sep
16
2026
CONGRESS
SCLCTargeted Therapies
Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan
Sep
13
2026
CONGRESS
SCLCADCs
ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months
Sep
13
2026
CONGRESS
Advanced NSCLCSCLCADCs
WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months
Sep
13
2026
CONGRESS
SCLC
MAVERICK: MRI surveillance without PCI improves cognitive failure-free survival in SCLC
Sep
13
2026
CONGRESS
SCLCADCs
Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302
Sep
12
2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC
WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response
Sep
10
2026
INDUSTRY NEWS
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC
Aug
23
2026
RESEARCH
BiomarkersSCLC
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A. Dingemans
Aug
03
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab improved cough, breathlessness and chest pain against chemotherapy in DeLLphi-304
C. RudinG. Mountzios
Jul
14
2026
RESEARCH
Advanced NSCLCSCLCADCs
ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
The Reading Room
Articles & Research
Oct
07
2026
RESEARCH
BiomarkersSCLC
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
P. Hofman
Oct
05
2026
RESEARCH
SCLCImmunotherapies
Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry
M. Hochmair
Oct
04
2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies
Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation
N. FrostM. ReckA. Cortellini
Oct
04
2026
RESEARCH
SCLCImmunotherapies
Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC
S. LiuM. ReckC. Rudin
Sep
30
2026
RESEARCH
Advanced NSCLCSCLCADCs
Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis
C. Rolfo
Sep
18
2026
CONGRESS
SCLCADCs
Ris-Rez improved OS against topotecan in relapsed SCLC in China
Sep
16
2026
CONGRESS
SCLCTargeted Therapies
Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan
Sep
13
2026
CONGRESS
SCLCADCs
ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months
Sep
13
2026
CONGRESS
Advanced NSCLCSCLCADCs
WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months
Sep
13
2026
CONGRESS
SCLC
MAVERICK: MRI surveillance without PCI improves cognitive failure-free survival in SCLC
Sep
13
2026
CONGRESS
SCLCADCs
Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302
Sep
12
2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC
WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response
Sep
10
2026
INDUSTRY NEWS
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC
Aug
23
2026
RESEARCH
BiomarkersSCLC
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A. Dingemans
Aug
03
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab improved cough, breathlessness and chest pain against chemotherapy in DeLLphi-304
C. RudinG. Mountzios
Jul
14
2026
RESEARCH
Advanced NSCLCSCLCADCs
ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon